Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 121
- Registration Number
- NCT00070135
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Radiation: iodine I 131 monoclonal antibody BC8Drug: busulfanDrug: cyclophosphamideProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationDrug: cyclosporineDrug: methotrexateOther: laboratory biomarker analysis
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00005940
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Pacific Northwest National Laboratory, Richland, Washington, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 451
- Registration Number
- NCT00060255
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT00003926
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00055653
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00054327
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00054340
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 82
- Registration Number
- NCT00053196
- Locations
- 🇺🇸
Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States
🇺🇸Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.